Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes

Sebastian Kreil, MD PhD, Lionel Adès, MD PhD, Martin Bommer, MD, Frank Stegelmann, MD, Mark E Ethell, MBBChir, MA, FRCP, FRCPath, Anna Lubking, MD, Peter Martin, MD, Ekkehard Eigendorff, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Andreas Hochhaus, MD, Andreas Reiter, MD

Blood (2015) 126 (23): 2812.

https://doi.org/10.1182/blood.V126.23.2812.2812

Published: 2015

Journal Articles

Complement Inhibition with Eculizumab in Patients with Cold Agglutinin Disease (CAD): Results from a Prospective Phase II Trial (DECADE Trial)

Alexander Röth, MD, Martin Bommer, MD, Andreas Hüttmann, MD, Dörte Herich-Terhürne, Nils Kuklik, PhD, Lenz Veronika, Hubert Schrezenmeier, MD, Ulrich Dührsen, MD

Blood (2015) 126 (23): 274.

https://doi.org/10.1182/blood.V126.23.274.274

Published: 2015

Journal Articles

Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study

Frank G. Rücker, Stephan Stilgenbauer, M.D., Martin Bommer, Daniela Späth, Silja Mack, Konstanze Döhner, Hartmut Döhner, MD, Richard F. Schlenk, MD

Blood (2010) 116 (21): 2184.

https://doi.org/10.1182/blood.V116.21.2184.2184

Published: 2010

Journal Articles

High-Dose RHAMM-R3 Peptide Peptide Vaccination for Patients with Vaccination for Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL)

Jochen Greiner, Anita Schmitt, Krzysztof Giannopoulos, Isabel Funk, Marta Heyduk, Markus Rojewski, Jinfei Chen, Marlies Goetz, Martin Bommer, Gerd Ritter, Phillipe Guillaume, Anna Dmoszynska, Hartmut Döhner, Michael Schmitt

Blood (2008) 112 (11): 2911.

https://doi.org/10.1182/blood.V112.11.2911.2911

Published: 2008

Journal Articles

Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.

Jochen Greiner, MD, Anita Schmitt, MD, Krzysztof Giannopoulos, MD, Jinfei Chen, MD, Marlies Goetz, Markus Rojewski, MD, Gerd Ritter, PhD, Sascha Gnjatic, PhD, Philippe Guillaume, PhD, Mark Ringhoffer, MD, Martin Bommer, MD, Richard F. Schlenk, MD, Peter Liebisch, MD, Donald Bunjes, MD, Hiroshi Shiku, PhD, Hartmut Dohner, MD, Michael Schmitt, MD

Blood (2007) 110 (11): 1806.

https://doi.org/10.1182/blood.V110.11.1806.1806

Published: 2007

Journal Articles

Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG.

Richard F. Schlenk, MD, Martin Bommer, MD, Mathias Schmid, MD, Stefan Fröhling, MD, Katrin Lehmann, Silja Groner, Rainer Hann, Jürgen Krauter, MD, Konstanze Döhner, MD, Arnold Ganser, MD, Martin Göttlicher, MD, Hartmut Döhner, MD

Blood (2005) 106 (11): 2800.

https://doi.org/10.1182/blood.V106.11.2800.2800

Published: 2005

NARROW

Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes

Complement Inhibition with Eculizumab in Patients with Cold Agglutinin Disease (CAD): Results from a Prospective Phase II Trial (DECADE Trial)

Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study

High-Dose RHAMM-R3 Peptide Peptide Vaccination for Patients with Vaccination for Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL)

Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.

Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG.

Email alerts

ASH Publications

American Society of Hematology

Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes

Complement Inhibition with Eculizumab in Patients with Cold Agglutinin Disease (CAD): Results from a Prospective Phase II Trial (DECADE Trial)

Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study

High-Dose RHAMM-R3 Peptide Peptide Vaccination for Patients with Vaccination for Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL)

Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.

Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only